The role of positron emission tomography in the drug development of M100907, a putative antipsychotic with a novel mechanism of action

Journal of Clinical Pharmacology

Volumn 39, Issue 8 SUPPL., 1999, Pages

  Offord, Steve J ^a   Wong, Dean F ^b   Nyberg, Svante ^c  

^a SANOFI   (France)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; DOPAMINE; FLUOROBENZENE; NEUROLEPTIC AGENT; PIPERIDINE DERIVATIVE; SEROTONIN ANTAGONIST;

BRAIN LEVEL; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFECT; HUMAN; METABOLISM; PHARMACEUTICS; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BRAIN CHEMISTRY; CLINICAL TRIALS; DOPAMINE; FLUOROBENZENES; HUMANS; PIPERIDINES; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS; TECHNOLOGY, PHARMACEUTICAL; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033172924     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1999.tb05933.x     Document Type: Article

References (26)

1. DiMasi JA: Trends in drug development: costs, times, and risks. Drug Inform J 1995;29:375-384.
2. Parsons ME, Garner A: Review article: drug development in gastroenterology - the changing view of industry. Aliment Pharmacol Ther 1995;9:457-463.
3. Mossinghoff GJ: Health care reform and pharmaceutical innovation. Drug Inform J 1995;29:1077-1090.
4. Vasella D: Novartis' role in 21st century drug development. Nature Biotech 1997;15:485.
5. American Psychiatric Association: Practice guidelines for major depressive disorder in adults. Am J Psychiatry 1993;150:1-26.
6. Metzler HY, Thompson PA, Lee MA, Ranjam R: Neurophysiologic deficits in schizophrenia: relation to social function and effects of antipsychotic drug treatment. Neuropsychopharmacology 1996;14(Suppl. 3):27S-33S.
7. Delay J, Deniker P, Harl JM: Utilisation en therpeutique psychiatrique d' une phenothiazine d'action centrale elective. Ann Med Psychol 1952;110:112-117.
8. Matthysse S: Dopamine and the pharmacology of schizophrenia: the state of evidence. J Psychiatr Res 1974;11:107-113.
9. Hippius H: The history of clozapine. Psychopharmacology 1988;99:3-5.
10. Metzler HY: The role of serotonin in schizophrenia and the place of serotonin-dopamine antagonist antipsychotics. J Clin Psychopharmacol 1995;15(Suppl. 1):2S-3S.
11. Kapur S, Remington G: Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 1996;153:466-476.
12. Sigmundson HK: Pharmacotherapy of schizophrenia: a review. Can J Psychiatry 1994;39(Suppl. 2):S70-S75.
13. Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C: Important issues in the drug treatment of schizophrenia. Schizophr Bull 1980;6:70-87.
14. Kane J, Honigfeld G, Singer J, Metzler HY for the Clozaril Collaborative Study Group: Clozapine for the treatment-resistant schizophrenic: a double-bind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796.
15. Tarsey D: Neuroleptic-induced extrapyramidal reactions: classification, description, and diagnosis. Clin Neuropharmacol 1983;6(Suppl. 1):S9-S26.
16. 2 receptor antagonist MDL 100,907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J Pharmacol Exp Ther 1993;266:684-691.
17. 3 mediated control of dopaminergic function. Psychopharmacology 1993;112:S60-S67.
18. 2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine. Eur J Pharmacol 1992;223:65-74.
19. Schmidt CJ, Fadayel GM: The selective 5-HT2 receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat. Eur J Pharmacol 1995;273:273-279.
20. Farde L: The advantages of using positron emission tomography in drug research. Trends Neurosci 1996;19:211-214.
21. Tamminga CA, Conley RR: The application of neuroimaging techniques to drug development. J Clin Psychiatry 1997;58(Suppl. 1):3-6.
22. 2 receptor occupancy studies and clinical response. Br J Psychiatry 1996; 168(Suppl. 29):40-44.
23. Lyon RA, Titeler M, Frost JJ, Whitehouse PJ, Wong DF, Wagner HN Jr, et al: Tritium-3-N-methylspiperone labels D2 dopamine receptors in basal ganglia and S2 serotonin receptors in cerebral cortex. J Neurosci 1986;6:2941-2949.
24. Andree B, Nyberg S, Ito H, Ginovart N, Brunner F, Jaquet F, et al: Positron emission tomographic analysis of dose-dependent MDL 100,907 binding to 5-hydroxytryptamine-2A receptors in the human brain. J Clin Psychopharmacol 1998;18:317-323.
25. 2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography. Neuropsychopharmacology 1997;17:175-185.
26. Brunner-Ferber F, Bhargava V, Offord SJ: The safety, tolerability, and pharmacodynamics of a selective 5-HT2A antagonist, M100907, following single and multiple oral dosing in healthy volunteers (abstract). Eur Neuropsychopharmacol 1998;8(Suppl. 2):2.091.